UPDATE 3-Bayer agrees cancer drug deal with Loxo worth up to $1.55 bln

Nov 14 (Reuters) - Germany's Bayer has bought the rights to jointly develop and commercialize two of Loxo Oncology's targeted cancer therapies in a deal that could earn the U.S. drug developer up to $1.55 billion in the next few years.